[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Nippon Medical School\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":49},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100601520",false,"NCT07111559","Lacunar Stroke hyperAcute Clinical Utilization of Novel Approach Regimens: Rt-PA vs. DAPT Randomised Clinical Trial","A Multicenter Randomized Controlled Trial Comparing Tissue Plasminogen Activator With Dual Antiplatelet Therapy for Patients With Hyperacute Single Perforating Artery Infarction","LACUNAR-tPA","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Acute ischemic stroke within 4.5 hours from onset. If onset time is unknown because of impaired consciousness or aphasia, use the \"last known well\" time.\n* A single perforating-artery infarct on brain MRI:\n\nlocated in the corona radiata, putamen, internal capsule, thalamus, or pons; solitary, mainly round or oval, with a maximum diameter ≤ 20 mm; lesions only in the centrum semiovale are not allowed, but extension from the above sites into the centrum semiovale is allowed.\n\n* No disability in daily life before the stroke (modified Rankin Scale ≤ 1).\n* National Institutes of Health Stroke Scale (NIHSS) score ≤ 5.\n* Written informed consent obtained.\n\nExclusion Criteria:\n\n* Antithrombotic therapy considered inappropriate because of active bleeding, low platelet count, or similar conditions.\n* Any contraindication to intravenous rt-PA, without blood pressures.\n* ≥ 50 % stenosis or occlusion of the artery responsible for the stroke \\* (see note below).\n* Diseases that require anticoagulation (e.g., atrial fibrillation, deep-vein thrombosis) \\*\n* Inability to take medicine orally.\n* Any other reason judged by the principal investigator or co-investigators to make participation inappropriate.\n\nNote: This study targets hyper-acute stroke within 4.5 hours. To avoid treatment delay, items marked with \\* must be judged using the similar examinations that each site normally performs before rt-PA administration.","ALL","18 Years",{"count":19,"type":20},500,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The goal of this clinical trial is to learn if a combination of antiplatelet drugs works better than intravenous tissue plasminogen activator to treat small ischemic stroke (lacunar stroke). The main questions it aims to answer are:\n\nIs a combination of antiplatelet drugs non-inferior to the current standard tissue plasminogen activator treatment? Does a combination of antiplatelet drugs reduce the bleeding complications than tissue plasminogen activator?\n\nResearchers will compare a combination of antiplatelet drugs to tissue plasminogen activator to see if a combination of antiplatelet drugs works to treat small ischemic stroke (lacunar stroke).\n\nParticipants will:\n\nTake a combination of antiplatelet drugs or be given intravenous tissue plasminogen activator Check the neurological status 3 months after stroke, in-person, by phone, or by mail.",[26,27,28],"Lacunar Stroke","Stroke","Ischemic Stroke",[30,31,32,33,34,35],"rt-PA","tissue-plasminogen activator","DAPT","dual antiplatelet therapy","minor stroke","lacunar stroke","RECRUITING","2026-06-04",{"date":39,"type":40},"2026-06-05","ACTUAL",{"date":42,"type":40},"2025-08-01",{"date":44,"type":20},"2029-03-31",{"name":46,"class":47},"Nippon Medical School","OTHER",28,""]